DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for Huntington disease-like 2 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHuntington disease-like 2 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for huntington disease-like 2 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
No drug has been tested in a randomised controlled trial specifically for Huntington disease-like 2. The 2009 review of emerging therapies in Huntington’s disease notes that even for the better-studied Huntington’s disease, no disease-modifying drug has been found clinically, and most trials are open-label, small, and focused on motor symptoms like chorea. A 2023 analysis of phase 3 trials for Huntington’s disease lists nine interventional studies, involving metformin, dextromethorphan/quinidine, deutetrabenazine, valbenazine, Cellavita HD, pridopidine, SAGE-718, and RO7234292 (RG6042). Four of these drugs are already FDA approved for other indications. None of these trials are reported to include patients with Huntington disease-like 2.
A 2012 study on transcriptional dysregulation in Huntington’s disease reports that TGase 2 inhibition normalised 40% of dysregulated gene expression in a Huntington’s disease cell model, and suggests that TGase 2 inhibitors might offer benefit. This work was done in cell models only, not in patients, and not in Huntington disease-like 2 models. No clinical data for TGase 2 inhibitors in any Huntington’s disease population are provided.
What is missing for Huntington disease-like 2 specifically: no dedicated clinical trials, no patient stratification by genetic subtype, no funding for a disease-specific drug development programme, and no evidence that any drug tested in Huntington’s disease would work in the distinct genetic context of Huntington disease-like 2.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Expert Opinion on Emerging Drugs · 2009 · 33 citations
Emerging drug therapies in Huntington's disease
AbstractHuntington's disease (HD) is a relentless neurodegenerative disease that results in profound disability through a triad of motor, cognitive and neuropsychiatric symptoms. At present, there are very few therapeutic interventions available with the exception of a limited number of drugs that offer mild symptomatic relief. Although the genetic basis of the disease has been identified, the mechanisms behind the cellular pathogenesis are still not clear and as a result no candidate drugs with the potential for disease modification have been found clinically until now. One of the major limitations in assessing the usefulness of drug treatments in HD is the lack of well-designed, double-blind, placebo-controlled clinical trials. Most studies have been open-label, using a small number of patients and tend to concentrate on the motor features of the disease, primarily the chorea. This review discusses the treatments now used for HD before evaluating the newer drugs at present being explored in both the clinic and in the laboratory in mouse models of the disease.
Pharmaceuticals · 2023 · 24 citations · open access
Huntington’s Disease Drug Development: A Phase 3 Pipeline Analysis
AbstractHuntington's Disease (HD) is a severely debilitating neurodegenerative disorder in which sufferers exhibit different combinations of movement disorders, dementia, and behavioral or psychiatric abnormalities. The disorder is a result of a trinucleotide repeat expansion mutation that is inherited in an autosomal dominant manner. While there is currently no treatment to alter the course of HD, there are medications that lessen abnormal movement and psychiatric symptoms. ClinicalTrials.gov was searched to identify drugs that are currently in or have completed phase III drug trials for the treatment of HD. The described phase III trials were further limited to interventional studies that were recruiting, active not recruiting, or completed. In addition, all studies must have posted an update within the past year. PubMed was used to gather further information on these interventional studies. Of the nine clinical trials that met these criteria, eight involved the following drugs: metformin, dextromethorphan/quinidine, deutetrabenazine, valbenazine, Cellavita HD, pridopidine, SAGE-718, and RO7234292 (RG6042). Of these drug treatments, four are already FDA approved. This systematic review provides a resource that summarizes the present therapies for treating this devastating condition that are currently in phase III clinical trials in the United States.
Targeting Transcriptional Dysregulation in Huntington’s Disease: Description of Therapeutic Approaches
Abstractcontrol mitochondrial biogenesis, chromatin structure, protein folding and DNA repair. In our results TGase 2 inhibition regulates the gene expression of PGC1-alpha, a transcriptional coactivator, and cytochrome c, a transcription factor, both important in mitochondrial biogenesis. TGase 2 inhibition can normalize 40% of the dysregulated gene expression in a HD cell model and for this reason TGase 2 may act as a broader transcriptional modulator. TGase 2 might negatively modulate transcription of neuroprotective genes, inhibiting the interaction between transcription factors and their co-activators and thereby repressing gene expression designed to compensate, for instance, for mitochondrial dysfunction in HD. Specific TGase 2 inhibitors, along with other therapies targeting transcriptional dysregulation, may offer a beneficial effect to this incurable disease.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
